Kornimate/medical-research-clean huggingface dataset:
laser treated scars and optical coherence tomography (oct)

Conditions: Scar

Summary: the purpose of this research study is to learn about the effects of the 2940 nm erbium: yttrium-aluminum-garnet (er:yag) laser on treating surgical scar using optical coherence tomography, a medical imaging device.


Eligibility criteria:
inclusion criteria: 1. adults age 18 years or older 2. patients should have fitzpatrick skin types of i-iv 3. patients should have mild to severe post-surgical scarring located on head and neck 4. scar lengths of at least 3 cm. 5. ability to understand and the willingness to sign a written informed consent document exclusion criteria: 1. the patient should not be receiving any additional systemic, topical, or intralesional treatment of the scars during the study 2. scar size less than 3 cm in length 3. pregnant or lactating females 4. fitzpatrick skin type of v-vi 5. scleroderma 6. photosensitivity 7. botulinum toxin injection, facial laser resurfacing, chemical peels, fillers, or usage of oral retinoid within the last 6 months.

Keywords: surgical scar
endometrial local injury to improve the outcome of embryo transfer

Conditions: Female Infertility Due to Nonimplantation of Ovum

Summary: the purpose of this study is to determine whether edometrial local injury improves the outcome of embryo transfer,and to find out more evidence about the time of trauma,the way of intervention,and the possible mechanism.

it is important to evaluate the efficacy of endometrial local injury in assisted reproductive technology(art),especially on the patients of recurrent implantation failure. although most trials proved the effectiveness of the intervention of local injury, the subjects of these trials are rarely the patients of repeated implantation failure(rif). moreover, the mechanism of endometrial injury is not clear.our trial may provide further basis for this purpose by comparing to the quality of endometrium in two-dimensional ultrasound.if the technique demonstrates efficacy, it would help the patients with rif caused by poor conditions of endometrium to deal with the problem of infertility.

Eligibility criteria:
inclusion criteria: * women with rif(≥2) of embyo transfer and uneven echo of endometrium on hcg day(12-14 days) * without operation history of uterine cavity in the previous three months * who agree to join in the study exclusion criteria: * women more than 40 years or less than 20 years * with infectious diseases or endocrine diseases * who refuse to participate in the experiment

Keywords: endometrial local injury repeated implatation failure embyo transfer
correlation between risankizumab's trough levels, clinical and biological remission in moderate to severe crohn's disease: a retrospective multicentric study

Conditions: Inflammatory Bowel Diseases

Summary: the goal of this observational study is to determine if, as with other therapeutics such as anti-tnf, trough levels of risankizumab are correlated with clinical and biological remission in patients with moderate to severe crohn's disease. as part of their regular biological surveillance, trough levels of risankizumab were mesured and clinical and biological data were collected to determine if biological and clinical remission criteria were met.

the treatment of chronic inflammatory bowel disease has undergone a number of therapeutic revolutions in recent years, with the emergence of new biotherapies. these include risankizumab, an anti-il23 p19, whose advance , motivate and fortify studies have demonstrated its efficacy in the induction and maintenance phases of crohn's disease. reimbursement in france for this indication is expected in the final quarter of 2024. while for first-line molecules such as anti-tnf alpha, the relationship between serum levels and clinical remission is accepted and allows to guide the therapeutic strategy for patients, it has yet to be demonstrated for new molecules of interest. we enrolled patients with moderate to severe crohn's disease on risankizumab in four centers. trough levels of risankizumab were mesured as a part of their regular medical surveillance routine. for each consultation, biological and clinical data were collected to determine wether patients were in remission (according to our primary outcome) or not. data were collected up to 18 months since the introduction of risankizumab. the objectives of this study were also to identify factors of primary or secondary failure of treatment, to determine clinical reponse rate, to evaluate tolerance and persistence of treatment.

Eligibility criteria:
inclusion criteria: * age ≥18 years * patients with moderate to severe crohn's disease * failure of at least one immunosuppressant and one anti-tnf alpha agent * patients on risankizumab * no opposition to study participation exclusion criteria: * age \< 18 years * uc * unclassified colitis * risankizumab prescribed to prevent post-operative relapse * any contraindication to risankizumab * refusal to participate in study
a prospective cohort study of igg4rd in china

Conditions: IgG4-related Disease

Summary: this is an cohort study to investigate the disease course and treatment response of patients with igg4-related disease.

immunoglobulin g4-related disease (igg4-rd) is a recently defined emerging clinical entity characterized by tissue infiltration by igg4-positive plasma cells, tissue fibrosclerosis and elevated serum igg4 concentration. in this study, patients with igg4-rd will be investigated, including clinical presentation, laboratory findings and imaging study. all patients will be treated by standard care and follow-uped for at least 6 months.

Eligibility criteria:
inclusion criteria: * males and females * age 18-75 years old with informed consent * patients with igg4-rd: 1. swelling, sclerosing and inflammatory involvement of one or more organ, including sclerosing pancreatitis, sclerosing cholangitis, inflammatory pseudotumors, retroperitoneal or mediastinal fibrosis, interstitial nephritis, hypophysitis, sclerosing dacryoadenitis, sialadenitis, inflammatory aortic aneurysm, lymphadenopathy, or other inflammatory conditions; 2. elevated serum igg4 (\>1.35 g/l) 3. histopathologic features of fibrosis and/or lymphocytic and polyclonal plasma cell infiltration (and igg4+ plasma cells on immunohistology when performed); 4. exclusion of other diseases. exclusion criteria: * females planning to bear a child recently or with childbearing potential * concurrent severe and/or uncontrolled and/or unstable diseases * patient with malignancy

Keywords: igg4-related disease igg4-rd
family integrated care in the nicu

Conditions: Premature Birth

Summary: in the highly technological environment of the modern neonatal intensive care unit (nicu), the infant is physically, psychologically and emotionally separated from its parents. recognition that this impedes parent- infant interaction and is detrimental to the infant, led to the development of programs such as family centered care, kangaroo care and skin-to-skin care1-3. however, they are based on the common premise that only nicu professionals with special skills can provide care for the infant. parents are relegated to a supportive role, and some have described themselves as voyeurs who are "allowed" to visit and hold their infants4. many feel anxious and unprepared to care for their infants after discharge5. in 1979, a shortage of nicu nurses in estonia prompted levin1,6 to implement a "humane" care model in which parents provided nursing care for the infant (except for administration of iv fluid and medication), while nurses provided teaching and guidance to parents. this resulted in 30% improvement in weight gain1,30% reduction in infections, 20% reduction in nicu length of stay, 50% reduction in nurse utilization and overall improved satisfaction among parents and staff \[personal communication, levin,a.\]. building on the estonian experience, we have developed a new family integrated care (fic) model that is adapted for the nicu environment in north america. in a pilot study at mount sinai hospital, toronto 46 infants and their families were enrolled in the study. preliminary results and feedback from parents and healthcare providers (hcp) show that the fic model is both feasible and safe, and may lead to improved outcomes including improved weight gain(paper submitted for publication). this study is a cluster randomized controlled trial in 16 tertiary level nicus, to evaluate the efficacy of the fic model in canada.


Eligibility criteria:
inclusion criteria: * \< 33 weeks gestational age at birth; * on no respiratory support or low level respiratory support (i.e., oxygen by cannula or mask, or continuous positive airway pressure (cpap); * a primary caregiver parent who is willing and able to commit to spending at least 8 hours per day with her/his infant between the hours of 0700 and 2000; * parental consent. exclusion criteria: * palliative care; * major life threatening congenital anomaly; * critical illness (unlikely to survive); * on high level of respiratory support (mechanical ventilator, high frequency oscillatory or jet ventilation, extra-corporeal membrane oxygenation) * parental request for early transfer to another hospital; * parental inability to participate (e.g., health, social or language issues that might inhibit their ability to communicate with the healthcare team).

Keywords: family integrated care family centered care nicu family centered care nicu parent program
quality of life in normogonadotropic anovulation

Conditions: Anovulation; Irregular Menses

Summary: among the causes of ovulation disorders (group ii of anovulation according to the world health organization classification), the dominant one is polycystic ovary syndrome (pcos), and the remaining cases are classified as hypothalamic-pituitary-ovarian axis dysfunction (hpod). the exact etiology of both entities is unknown. to diagnose pcos, the rotterdam criteria must be met and other conditions that may cause hyperandrogenism or ovulation disorders must be excluded. pcos is more often accompanied by other endocrine and metabolic disorders, such as obesity, dyslipidemia, hyperandrogenism, insulin resistance, diabetes, hyperprolactinemia and thyroid diseases, as well as infertility due to ovulation defect. these conditions not only significantly reduce quality of life (qol), but also lead to an increased risk of cardiovascular disease, metabolic syndrome, adverse obstetric outcomes and an increased risk of endometrial cancer, further impairing qol.

a prospective questionnaire study will be conducted regarding the quality of life among women undergoing hormonal diagnostics due to anovulation. the study will include women aged 18-45 with ovulation disorders: pcos (arm 1) and hpod (arm 2). the quality of life will be assessed using the self-assessment method using the sf-36 questionnaire (short form health survey). the questionnaire is intended for a subjective assessment of health status. it consists of 11 questions containing 36 statements that allow you to determine eight quality of life indicators, i.e.: physical functioning, role limitations due to physical health, role limitations due to emotional problems, energy/fatigue, emotional well-being, social functioning, pain, general health, health change. the percentage score on a scale of 0-100% in each of the 8 life domains will be compared between both arms of the study.

Eligibility criteria:
inclusion criteria: * menstrual cycle length \ 35 days * age 18-45 years exclusion criteria: * previous ovarian surgery

Keywords: anovulation irregular menstruation pcos hpod quality of life
intervention in spirituality at the end of life. the kibo protocol

Conditions: Palliative Care

Summary: this work aims to study the benefits that the therapeutic interview kibo in palliative care patients can have for spirituality. a parallel randomized controlled trial of two groups was performed. information was collected on 60 palliative care patients during the moments before and after the intervention.


Eligibility criteria:
inclusion criteria: 1. to be 18 or more years of age. 2. being in advanced or terminal disease phase (following world health organization criteria). 3. to have preserved cognitive capacity. 4. to have signed the informed consent. exclusion criteria: a) estimated time of survival: patients with a life expectancy of two weeks or less will not be intervened.

Keywords: spirituality intervention study
idebenone treatment of early parkinson's diseasesymptoms

Conditions: Oxidative Stress is an Important Cause of Parkinson's Disease

Summary: on may 30,2018 ,investigators intend to conduct a multicenter, randomized, double-blind, placebo-controlled study of idebenone in the treatment of early-stage parkinson's disease with motor and non-motor symptoms which is to observe the therapeutic effect of idebenone on motor symptoms and non-motor symptoms in patients with early parkinson's disease。

this clinical trail was a multicenter, parallel, randomized, double-blind, placebo-controlled study led by professor liu chunfeng from the second affiliated hospital of suzhou university which consisted of 15 sub-centers with a total of 180 subjects. this clinical study is divided into two phases: the first stage: double-blind period, 24 weeks. three queues containing idebenone 180 mg/d,360 mg/d and placebo. the second stage: open label extension period, 24 weeks. all enrolled participants continued to take idebenone 180 mg/d to study the long-term effects of idebenone.

Eligibility criteria:
inclusion criteria: * (1) male or female, age \> 30 years old, ≤ 80 years old; * (2) conforms to the "diagnostic criteria for parkinson's disease" developed by the 2015 international association of sports disabilities (mds); * (3) patients with early parkinson's disease, duration \<3 years, hoehn-yahr classification:1-3, mmse scale score ≥ 24 points; * (4)receiving a stable dose of dopamine agonist or monoamine oxidase type b inhibitor for treatment before the enrollment; * (5) the subjects need to sign the informed consent form（icf） exclusion criteria: * (1)patients with disturbance of consciousness, aphasia and mental illness; patients with major depression (had scale score ≥ 15 points) * (2)patients with parkinson's superimposition syndrome and patients with secondary parkinson's syndrome (hepatolenticular degeneration, hepatic encephalopathy, cerebellar disease, hydrocephalus, parathyroid disease, etc.) * (3)patients who have long-term use of dopamine blockers (such as potent neuroleptics, sibutramine, reserpine, metoclopramide, etc.); * (4)patients who have taken coenzyme q10 or idebenone within three months; * (5) patients taking amantadine and levodopa need to stop taking the drug for more than one month before the enrollment; * (6)patients with severe cardiopulmonary dysfunction, liver and kidney dysfunction (more than 3 times normal); * (7)patients who cannot cooperate with the neuropsychological test; * (8) patients with poor compliance, not following the prescribed treatment regimen.
unravelling tumour biology in ovarian cancer with precision imaging

Conditions: High Grade Serous Ovarian Cancer

Summary: the objective of this study is to explore the integration of in vivo and ex vivo of mri with histology and molecular assessments to advance non-invasive characterization of tumor heterogeneity in high-grade serous ovarian cance

after being informed about the study and potential risks, all patient giving wirtting informed consent. during surgery, tissue and blood samples will be conserved for the study. in this study will be compared images obtained in vivo before surgical management, ex vivo images obtained on excised tissues during surgery, histological data obtained during surgery.

Eligibility criteria:
inclusion criteria: * patient aged \>18 * pathologically proven hgsoc at an advanced stage (figo iiib or iiic) which can benefit from surgery with or without prior neoadjuvant treatment * willingness and ability to comply with planned visits, treatment plan, laboratory tests and other study procedures, * patient who has given informed, written and express consent, * patient affiliated with a french health insurance scheme. exclusion criteria: * early-stage disease (figo \<iiib) or presence of extraperitoneal metastases, * patient who will not have surgery * patient whose regular follow-up is impossible for psychological, family, social or geographical reasons, * patient under guardianship, curatorship or safeguarding of justice, * pregnant and/or nursing patient, * patient with a history of other cancers within 5 years/10 years prior to inclusion

Keywords: radiomics ovarian cancer genomics proteomics immune tumor microenvironment
vitamin d status and immune function

Conditions: Vitamin D Deficiency

Summary: the purpose of this study is to examine the relationship between vitamin d status and immunity.

vitamin d is mainly obtained from the sun and follows a seasonal pattern, with vitamin d levels peaking in summer and reaching a trough during winter. vitamin d deficiency is associated with impaired immunity. however, knowledge of vitamin d deficiency with in vivo immunity is limited. this observational study aims to investigate the relationship between vitamin d status and the in vivo immunity.

Eligibility criteria:
inclusion criteria: * passed medical assessment by medical doctor * passed audio test (this is part of medical assessment) * met physical fitness requirements exclusion criteria: • medically deferred by medical doctor
depakote er therapy for mania comorbid with substance abuse

Conditions: Bipolar Disorder; Mania; Substance Abuse; Substance Dependence

Summary: the purpose of this study is to ascertain whether depakote er (divalproex er) has efficacy in the treatment of patients with bipolar disorder in the manic phase, who also have comorbid substance abuse diagnoses. it is proposed that depakote er will decrease scores on the young mania rating scale and the substance abuse time line follow back.

this study will be performed in male and female subjects with a diagnosis of bipolar disorder in the manic phase of the illness who also have a comorbid diagnosis of substance abuse. this population is selected so the efficacy of depakote er in this population can be tested.

Eligibility criteria:
inclusion criteria: 1. ages 19 - 65. 2. diagnosis of mania with comorbid substance confirmed by structured clinical interview for dsm-iv. 3. comorbid diagnoses of anxiety and/or personality disorders are permitted. 4. ability to provide signed informed consent. 5. stable general medical health. 6. ability to attend outpatient research clinic. exclusion criteria: 1. dangerous to self or others. 2. pregnancy, inability or unwillingness to use approved methods of birth control. 3. inability or unwillingness to provide signed informed consent. 4. diagnosis of schizophrenia, major depressive disorder. 5. inability to attend outpatient research clinic. 6. medical conditions, which would preclude use of depakote. 7. need for ongoing treatment with medication other than depakote er, such as antipsychotic medication. 8. medical instability defined as likelihood of needing to change prescription medication during the course of the study.

Keywords: bipolar disorder mania substance abuse substance dependence comorbid
tap vs ql for postoperative analgesia after diep free flap breast reconstruction

Conditions: Breast Cancer

Summary: the purpose of this study is to compare the efficacy of transversus abdominus plane (tap) block and quadratus lumborum (ql) block on the quality of recovery after breast reconstruction with deep inferior epigastric perforator (diep) flap.

breast reconstruction after mastectomy has seen continued growth and popularity in recent years secondary to improved surgical techniques and improved patient awareness and understanding. while implant-based reconstruction remain the most popular option, autologous tissue transfer, reconstruction of the breast with a patient's own tissues, has emerged as the gold standard for breast reconstruction, most commonly performed with abdominally-based flaps, such as the deep inferior epigastric perforator (diep) flap. postoperative pain can be a difficult challenge in patients who have undergone diep flap. patients with worse postoperative pain control report worse overall satisfaction with their surgical experience. a multimodal analgesia protocol is a key component in the postoperative care after diep flap. regional nerve blocks present an adjunct to these protocols that can potentially improve the quality of recovery of these patients. transversus abdominus plane (tap) blocks have been shown to be a safe and effective technique to manage postoperative pain at the abdomen in this population; lowering usage of opiates, shortening length of stay and reducing episodes of nausea and vomiting. tap's efficacy is well-established and documented for postoperative analgesia in abdominal surgery. this can be done preoperatively by an anesthetist via ultrasound-guidance or, using traditional technique of direct visualization, intraoperatively by the operating surgeon. surgeon-performed intra-operative tap block are often preferred as it is less time-consuming. tap block has become the standard abdominal regional nerve block to perform during this procedure. more recently, ql block has emerged as an alternative to tap block for lower abdominal surgery. the ql block is an ultrasound-guided fascial plane block performed by an anesthetist for anterior abdominal wall analgesia. this study will compare ql block to tap block in patients undergoing diep free flap breast reconstruction.

Eligibility criteria:
inclusion criteria: * women (age 18 years or older) who are booked for abdominally based free flap for breast reconstruction * patients with america society of anesthesiologists (asa) physical status class i, ii and iii exclusion criteria: * patients not consenting for regional block * patients allergic to local anesthetics and adjuvants * patients with america society of anesthesiologists (asa) physical status class iv and v * patients with any baseline opiate consumption * presence of infection at needle insertion site * patients with coagulopathy (inr\>1.3) * patients with thrombocytopenia (platelets\<100) * patients on therapeutic anticoagulation